{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T23:46:43Z","timestamp":1770680803600,"version":"3.49.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.pnpbp.2017.04.030","type":"journal-article","created":{"date-parts":[[2017,4,26]],"date-time":"2017-04-26T04:46:11Z","timestamp":1493181971000},"page":"140-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Rat brain CYP2D enzymatic metabolism alters acute and chronic haloperidol side-effects by different mechanisms"],"prefix":"10.1016","volume":"78","author":[{"given":"Sharon","family":"Miksys","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fariba Baghai","family":"Wadji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgor Cole","family":"Tolledo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Remington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose N.","family":"Nobrega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel F.","family":"Tyndale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2017.04.030_bb0005","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.neulet.2015.02.028","article-title":"Effects of haloperidol and clozapine administration on oxidative stress in rat brain, liver and serum","volume":"591","author":"Andreazza","year":"2015","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0010","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/0024-3205(96)00475-4","article-title":"Haloperidol and its tetrahydropyridine derivative (HPTP) are metabolized to potentially neurotoxic pyridinium species in the baboon","volume":"59","author":"Avent","year":"1996","journal-title":"Life Sci."},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0015","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13643-016-0391-5","article-title":"Pharmacological interventions for delirium in intensive care patients: a protocol for an overview of reviews","volume":"5","author":"Barbateskovic","year":"2016","journal-title":"Syst. Rev."},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0020","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.pbb.2007.10.009","article-title":"Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain","volume":"88","author":"Bishnoi","year":"2008","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0025","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1124\/jpet.111.189100","article-title":"Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats","volume":"340","author":"Bordia","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0030","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.pbb.2005.05.002","article-title":"Ebselen attenuates haloperidol-induced orofacial dyskinesia and oxidative stress in rat brain","volume":"81","author":"Burger","year":"2005","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0035","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1054-3589(08)57010-4","article-title":"Preclinical behavioral models for predicting antipsychotic activity","volume":"57","author":"Castagne","year":"2009","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0040","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.pnpbp.2012.10.018","article-title":"Oxidative stress and tardive dyskinesia: pharmacogenetic evidence","volume":"46","author":"Cho","year":"2013","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0045","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1124\/dmd.114.058719","article-title":"Nicotine pharmacokinetics in rats is altered as a function of age, impacting the interpretation of animal model data","volume":"42","author":"Craig","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0050","first-page":"389","article-title":"Neurobiological basis of dyskinetic effects induced by antipsychotics: the contribution of animal models","volume":"20","author":"Creed","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0055","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1124\/dmd.31.3.282","article-title":"Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices","volume":"31","author":"Edwards","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0060","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0014-2999(79)90201-2","article-title":"Brain distribution of propranolol in the rat","volume":"55","author":"Elghozi","year":"1979","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0065","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0024-3205(96)00656-X","article-title":"Two pyridinium metabolites of haloperidol are present in the brain of patients at post-mortem","volume":"60","author":"Eyles","year":"1997","journal-title":"Life Sci."},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0070","first-page":"1638","article-title":"In vitro characterization of the metabolism of haloperidol using recombinant cytochrome P450 enzymes and human liver microsomes","volume":"29","author":"Fang","year":"2001","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0075","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1365\/s10337-004-0224-x","article-title":"Determination of dextromethorphan and dextrorphan in human urine by high performance liquid chromatography for pharmacogenetic investigations","volume":"59","author":"Flores-Perez","year":"2004","journal-title":"Chromatographia"},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0080","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00228-005-0051-5","article-title":"Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects","volume":"61","author":"Funck-Brentano","year":"2005","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0085","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jemermed.2015.03.023","article-title":"A randomized controlled trial of intravenous haloperidol vs. intravenous metoclopramide for acute migraine therapy in the emergency department","volume":"49","author":"Gaffigan","year":"2015","journal-title":"J. Emerg. Med."},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0090","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/npp.2015.40","article-title":"Effect of brain CYP2B inhibition on brain nicotine levels and nicotine self-administration","volume":"40","author":"Garcia","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0095","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1570-0232(02)01042-5","article-title":"Determination of dextromethorphan and its metabolites in rat serum by liquid-liquid extraction and liquid chromatography with fluorescence detection","volume":"788","author":"Hendrickson","year":"2003","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0100","first-page":"11","article-title":"Successful treatment of suspected cannabinoid hyperemesis syndrome using haloperidol in the outpatient setting","author":"Jones","year":"2016","journal-title":"Case Rep. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0105","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/0006-2952(93)90166-T","article-title":"Primary and secondary oxidative metabolism of dextromethorphan. In vitro studies with female Sprague-Dawley and dark agouti rat liver microsomes","volume":"45","author":"Kerry","year":"1993","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0110","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1007\/s00213-014-3582-6","article-title":"Oxidative stress and the antipsychotic-induced vacuous chewing movement model of tardive dyskinesia: evidence for antioxidant-based prevention strategies","volume":"231","author":"Lister","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0115","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pnpbp.2016.08.010","article-title":"Lipoic acid and haloperidol-induced vacuous chewing movements: implications for prophylactic antioxidant use in tardive dyskinesia","volume":"72","author":"Lister","year":"2017","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0120","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1517\/14728214.2015.1050376","article-title":"Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials","volume":"20","author":"Lockwood","year":"2015","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0125","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000445802","article-title":"Genetics of common antipsychotic-induced adverse effects","volume":"2","author":"MacNeil","year":"2016","journal-title":"Mol. Neuropsychiatry"},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0130","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.neuropharm.2008.07.017","article-title":"Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment","volume":"55","author":"Mann","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0135","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/j.neurobiolaging.2011.08.014","article-title":"The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson's disease patients","volume":"33","author":"Mann","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0140","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1001\/archpsyc.1994.03950040046006","article-title":"Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind, placebo-controlled study in patients with and without tics","volume":"51","author":"McDougle","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"issue":"7","key":"10.1016\/j.pnpbp.2017.04.030_bb0145","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/npp.2015.32","article-title":"Nicotine increases codeine analgesia through the induction of brain CYP2D and central activation of codeine to morphine","volume":"40","author":"McMillan","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0150","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1503\/jpn.120133","article-title":"Cytochrome P450-mediated drug metabolism in the brain","volume":"38","author":"Miksys","year":"2013","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0155","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006271.pub3","article-title":"Haloperidol for the treatment of nausea and vomiting in palliative care patients","volume":"2","author":"Murray-Brown","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0160","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1248\/bpb.24.988","article-title":"Inactivation of rat cytochrome P450 2D enzyme by a further metabolite of 4-hydroxypropranolol, the major and active metabolite of propranolol","volume":"24","author":"Narimatsu","year":"2001","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0165","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/FTD.0b013e31811f394d","article-title":"Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome","volume":"29","author":"Panagiotidis","year":"2007","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0170","doi-asserted-by":"crossref","first-page":"555","DOI":"10.31887\/DCNS.2014.16.4\/jpouget","article-title":"Pharmacogenetics and outcome with antipsychotic drugs","volume":"16","author":"Pouget","year":"2014","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0175","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD009377.pub2","article-title":"Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation)","volume":"14","author":"Powney","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0180","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1046\/j.1365-2125.2001.01313.x","article-title":"Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol","volume":"51","author":"Shin","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0185","first-page":"11","article-title":"Interventions for preventing delirium in hospitalised non-ICU patients","author":"Siddiqi","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0190","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12888-015-0578-7","article-title":"An evaluation of variation in published estimates of schizophrenia prevalence from 1990 horizontal line 2013: a systematic literature review","volume":"15","author":"Simeone","year":"2015","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0195","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.tox.2015.10.002","article-title":"Subacute nicotine co-exposure has no effect on 2,2\u2032,3,5\u2032,6-pentachlorobiphenyl disposition but alters hepatic cytochrome P450 expression in the male rat","volume":"338","author":"Stamou","year":"2015","journal-title":"Toxicology"},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0200","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/0006-291X(90)91936-M","article-title":"Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats","volume":"166","author":"Subramanyam","year":"1990","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0205","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/0006-291X(91)91228-5","article-title":"Identification of potentially neurotoxic pyridinium metabolite in the urine of schizophrenic patients treated with haloperidol","volume":"181","author":"Subramanyam","year":"1991","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0210","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/sj.mp.4001009","article-title":"Significant dissociation of brain and plasma kinetics with antipsychotics","volume":"7","author":"Tauscher","year":"2002","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0215","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ejps.2006.06.005","article-title":"Cytochrome P450 (CYP) inhibition screening: comparison of three tests","volume":"29","author":"Turpeinen","year":"2006","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0220","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1038\/sj.npp.1300233","article-title":"Differential effects of within-day continuous vs. transient dopamine D2 receptor occupancy in the development of vacuous chewing movements (VCMs) in rats","volume":"28","author":"Turrone","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0225","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s00213-002-1259-z","article-title":"The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats","volume":"165","author":"Turrone","year":"2003","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0230","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0090-9556(24)15243-9","article-title":"Characterization of cytochrome P-450 2D1 activity in rat brain: high-affinity kinetics for dextromethorphan","volume":"27","author":"Tyndale","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0235","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/10298420290007628","article-title":"Metabolic studies on haloperidol and its tetrahydropyridinyl dehydration product (HPTP) in C57BL\/6 mouse brain preparations","volume":"4","author":"Usuki","year":"2002","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0240","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1055\/s-2007-1016985","article-title":"Does smoking reduce the risk of neuroleptic parkinsonoids?","volume":"21","author":"Wagner","year":"1988","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0245","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/JCP.0000000000000319","article-title":"The influence of the CYP3A4*22 polymorphism and CYP2D6 polymorphisms on serum concentrations of aripiprazole, haloperidol, pimozide, and risperidone in psychiatric patients","volume":"35","author":"van der Weide","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0250","series-title":"Who Model List of Essential Medicines 19th Edition","author":"WHO","year":"2015"},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0255","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/YCO.0b013e3283366643","article-title":"Why do patients with schizophrenia smoke?","volume":"23","author":"Winterer","year":"2010","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0260","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0006-8993(97)01551-5","article-title":"Effects of haloperidol metabolites on neurotransmitter uptake and release: possible role in neurotoxicity and tardive dyskinesia","volume":"788","author":"Wright","year":"1998","journal-title":"Brain Res."},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0265","first-page":"54","article-title":"Chronic nicotine treatment induces rat CYP2D in the brain but not in the liver: an investigation of induction and time course","volume":"33","author":"Yue","year":"2008","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0270","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/rcm.2914","article-title":"Liquid chromatography\/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat plasma","volume":"21","author":"Zhang","year":"2007","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0275","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jchromb.2007.03.045","article-title":"Sensitive liquid chromatography\/tandem mass spectrometry method for the determination of the lipophilic antipsychotic drug chlorpromazine in rat plasma and brain tissue","volume":"854","author":"Zhang","year":"2007","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.pnpbp.2017.04.030_bb0280","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/j.bcp.2013.04.014","article-title":"First demonstration that brain CYP2D-mediated opiate metabolic activation alters analgesia in vivo","volume":"85","author":"Zhou","year":"2013","journal-title":"Biochem. Pharmacol."}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027858461730088X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027858461730088X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:25:57Z","timestamp":1750206357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027858461730088X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":56,"alternative-id":["S027858461730088X"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2017.04.030","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rat brain CYP2D enzymatic metabolism alters acute and chronic haloperidol side-effects by different mechanisms","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2017.04.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}